Compare Mesoblast Limited (MESO) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs 3M Company — how do they compare? Mesoblast Limited trades at $16.25 (market cap $2.17B), while 3M Company trades at $174.74 (market cap $82.99B). The key difference: 3M Company is far larger — about 38.2× Mesoblast Limited's market cap, and 3M Company pays a 1.96% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MMM | |
|---|---|---|
Market Cap | $2.17B | $82.99B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $174.61 |
52-Week Low | $12.88 | $141.10 |
Enterprise Value | $2.17B | $91.39B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
3M (MMM) trades at $159.98, up 0.09% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.14, exceeding the $1.98 estimate, and maintains a strong net income margin of 11.14%. Analysts are divided with a 48.49% buy rating, and the consensus price target is $149.75. Recent news highlights Q2 earnings expectations and new partnerships, such as the Airbus A220 supply agreement.
The outlook for MMM is mixed; earnings momentum and cost optimization support growth, but valuation ratios like a P/E of 30.8 suggest premium pricing. Risks include consumer segment weakness and debt levels. Upside depends on Q2 results meeting the $2.27 EPS forecast, while downside could stem from macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
